selective agonist (Ki
= 3.4 nM). Approx. 200-fold selective over CB1
receptors. Active in vivo
, reducing spasticity in a murine model of multiple sclerosis. Activity also enhances the release of IL-10 by LPS/IFN-γ
-stimulated macrophages and results in downregulation of the IL-12 subunit p40. Also available in water soluble emulsion
(Cat. No. 1783).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Other Product-Specific Information:
Pharmacology of cannabinoid receptor ligands.
Cannabinoids control spasticity and tremor in a multiple sclerosis model.
Baker et al.
Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling.
Correa et al.
3-(1'-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor.
Huffman et al.
The citations listed below are publications that use Tocris products. Selected citations for JWH 133 include:
Showing Results 1 - 10 of 24